Hydrogenology
Hydrogenology editorial study record

Hydrogen-rich water reduces inflammatory responses and prevents apoptosis of peripheral blood cells in healthy adults: a randomized, double-blind, controlled trial

Sim M et al. · Sci Rep. 2020;10(1):12130.

HumanH₂-rich waterPublished 2020
Study record, not medical adviceThis page reports one source and Hydrogenology’s source-text extraction. It does not establish that molecular hydrogen is effective, safe or appropriate for any person. Human, animal and laboratory evidence must not be treated as equivalent.
Source and classification

What kind of evidence is this?

Evidence stream

Human

Reported design

Randomized double-blind placebo-controlled parallel trial

Research topic

Immune and inflammatory conditions

Administration classification

H₂-rich water

Study result signal

Not reported in this record.

Outcome type

Not reported in this record.

Reported in the source

Methods at a glance

Population or model

Healthy adults aged 20–59 years

Sample

41 randomized; 38 completed and were analyzed: H₂ water n=20, plain water n=18

Duration

4 weeks

Intervention

Three 500 mL bottles of hydrogen-rich water daily; 1.5 L/day

Hydrogen form

H₂ dissolved in water — H₂ only, not Brown’s gas.

H₂ specification

0.753 ± 0.012 mg/L dissolved H₂.

H₂ flow

Not applicable — oral water, not gas inhalation.

O₂ delivered with H₂

No O₂ was co-delivered as part of the intervention.

Comparator

1.5 L/day plain water

Reported, not endorsed

Outcomes and reported result

Outcomes measured

Antioxidant and oxidative-stress markers, PBMC apoptosis and immune-cell subsets, exploratory RNA sequencing

Reported result

Whole-group changes in BAP, d-ROMs and 8-OHdG did not differ. BAP improved only in an age subgroup; PBMC apoptosis and CD14 frequency were lower. RNA sequencing used only three participants per group.

Results-extraction completeness

Methods, main results, funding and conflict statement checked in the free full text; independent appraisal remains incomplete.

A reported association, difference or mechanism is not automatically a clinical benefit. Null findings, outcome type, study design and precision all matter.

Interpretation limits

Cautions and applicability

Design and reporting cautions

Short study in healthy adults; the age result was subgroup-based and omics involved three people per arm. Coway and a Korean public grant supported the study; authors declared no competing interests.

Applies directly to

Healthy adults aged 20–59 under this four-week protocol, not patients with inflammatory disease.

Preliminary appraisal framework

Not reported in this record.

Preliminary risk-of-bias status

Not reported in this record.

Appraisal rationale

Not reported in this record.

No single-study GRADE certainty rating is assigned. Certainty is assessed by important outcome across a complete eligible evidence set, not by attaching a final grade to one source.

Provenance

Sources and record status

Identifiers

PMID: 32699287 · DOI: 10.1038/s41598-020-68930-2

Publisher access

Open-access article.

Extraction basis

Free full text on PMC; identifiers cross-checked in PubMed.

Record revision

2026-08-10